Key stats
About Amplify ETF Trust Amplify Treatments, Testing and Advancements ETF
Expense ratio
0.68%
Home page
Inception date
Jun 17, 2020
GERM provides a targeted exposure to a subsector of the healthcare industry. The passively managed fund holds firms that research, develop, and commercialize treatments or vaccines against infectious diseases, as well as companies involved in the research, development, manufacturing, and provision of biological tests for patients. Eligible firms must meet minimum market-cap and liquidity requirements, and have an operating company structure. Selected stocks are weighted in tiers: a) mega-caps or firms with market-cap of $15 billion or more, are equally weighted within an aggregate allocation of 10%, b) the top five constituents after excluding mega-caps receive 6% weight each, and c) the remaining stocks are weighted by market-cap, subject to a 4% cap per holding. The index is rebalanced and reconstituted quarterly. On January 29, 2024, the fund acquired all assets and liabilities of the ETFMG Treatments Testing and Advancements ETF, morphing into a new ETF that employs the same strategy.
Classification
What's in the fund
Exposure type
Health Technology
Health Services
Stock breakdown by region